Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.

Elaine M WalshAyca GucalpSujata PatilMarcia EdelweissDara S RossPedram RazaviShanu ModiNeil M IyengarRachel SanfordTiffany Troso-SandovalMila GorskyJacqueline BrombergPamela DrullinskyDiana LakeSerena WongPatricia Ann DeFuscoNicholas LamparellaRanja GuptaTasmila TabassumLeigh Ann BoyleArtavazd ArumovTiffany A Traina

Published in: Breast cancer research and treatment (2022)

This clinical trial demonstrates that adjuvant enzalutamide is a feasible and well-tolerated regimen in patients with an early-stage AR + TNBC. Randomized trials in the metastatic setting may inform patient selection through biomarker development; longer follow-up is needed to determine the effect of anti-androgens on DFS and OS in this patient population.

Keyphrases

early stage
prostate cancer
clinical trial
sentinel lymph node
case report
squamous cell carcinoma
small cell lung cancer
phase ii
randomized controlled trial
study protocol
open label
lymph node
rectal cancer